US 9,808,509 B2
Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
William H. Frey, II, White Bear Lake, MN (US); Leah Ranae Bresin Hanson, Vadnais Heights, MN (US); and Shyeilla V. Dhuria, Minneapolis, MN (US)
Assigned to HealthPartners Research Foundation, Bloomington, MN (US)
Filed by William H. Frey, II, White Bear Lake, MN (US); Leah Ranae Bresin Hanson, Vadnais Heights, MN (US); and Shyeilla V. Dhuria, Minneapolis, MN (US)
Filed on Jun. 6, 2008, as Appl. No. 12/134,385.
Claims priority of provisional application 60/942,696, filed on Jun. 8, 2007.
Prior Publication US 2008/0305077 A1, Dec. 11, 2008
Int. Cl. A61K 38/20 (2006.01); A61K 9/00 (2006.01); A61K 31/16 (2006.01); A61K 33/24 (2006.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/28 (2006.01); A61K 38/30 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/2006 (2013.01) [A61K 9/0043 (2013.01); A61K 31/16 (2013.01); A61K 33/24 (2013.01); A61K 38/1841 (2013.01); A61K 38/191 (2013.01); A61K 38/28 (2013.01); A61K 38/30 (2013.01); A61K 45/06 (2013.01)] 16 Claims
 
1. A method for treating a disease or condition within a patient's brain, with increased targeting efficiency for at least one delivery target related to anatomical structures located in the rostral portion of the patient's brain compared to any delivery targets in the caudal portion of the patient's brain, and increased delivery of at least one therapeutic compound thereto compared with the caudal portion of the patient's brain, comprising:
providing at least an effective amount of at least one therapeutic compound capable of treating the disease or condition;
providing at least an effective amount of at least one vasoconstrictor;
administering the at least an effective amount of the at least one therapeutic compound to the upper third of the patient's nasal cavity;
administering the at least an effective amount of the at least one vasoconstrictor to the upper third of the patient's nasal cavity;
thereby increasing targeting efficiency of the administered amounts of the at least one therapeutic compound to the patient's olfactory epithelium and thereby enabling at least an effective amount of the at least one therapeutic compound to bypass the patient's blood-brain barrier;
delivering an effective amount of the at least one therapeutic compound to at least one target in the rostral portion of the patient's brain, with increased efficiency as compared with the delivery efficiency of the at least one therapeutic compound within the caudal portion of the patient's brain;
minimizing the amount of the at least one therapeutic compound absorbed into the patient's blood and/or peripheral tissues; and
treating the patient's disease or condition.